A carregar...
Dynamics of chronic myeloid leukemia response to dasatinib, nilotinib, and high-dose imatinib
Treatment with the tyrosine kinase inhibitor imatinib is the standard of care for newly diagnosed patients with chronic myeloid leukemia. In recent years, several second-generation inhibitors – such as dasatinib and nilotinib – have become available: these promise to overcome some of the mutations a...
Na minha lista:
| Publicado no: | Haematologica |
|---|---|
| Main Authors: | , , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Ferrata Storti Foundation
2014
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4222479/ https://ncbi.nlm.nih.gov/pubmed/25216683 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3324/haematol.2013.085977 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|